eXmoor Pharma
Bristol, UK
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-29
78.7
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (3)
○ EMA GMP
✓ MHRA GMP (1)
Quick Facts: eXmoor Pharma
- Signal Score
- 78.7/100 (as of 2026-04-29)
- Quality Compliance
- 100.0/100 — No FDA inspection records found for this manufacturer
- Headquarters
- Bristol, UK
- Modalities
- Cell Therapy, AAV
- Active Programs
- No ClinicalTrials.gov matches confirmed — 1 partnership announcement in press
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About eXmoor Pharma
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
MHRA GMP Certificates1 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy, AAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
1 manufacturing site: Bristol, UK
Modalities: Cell Therapy, AAV
Capacity assessment: 60.0/100
Sites: Bristol, UK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press3 articles
1 manufacturing site: Bristol, UK
Modalities: Cell Therapy, AAV
Capacity assessment: 60.0/100
eXmoor Pharma MHRA GMP Compliance 1 certificates
2025-11
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 32954 Insp GMP/IMP 32954/36082496-0002[I] | EXMOOR PHARMA CONCEPTS LTD | BRISTOL BS34 5TA | 2025-11-12 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Jul 04, 2026
Recent News 3 articles
eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing - BioPharma APAC
eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing BioPharma APAC
eXmoor Pharma appoints Manuel Balbuena as Chief Commercial Officer - Pharmafile
eXmoor Pharma appoints Manuel Balbuena as Chief Commercial Officer Pharmafile
eXmoor Pharma Appoints Manuel Balbuena Chief Commercial Officer - Contract Pharma
eXmoor Pharma Appoints Manuel Balbuena Chief Commercial Officer Contract Pharma
Frequently Asked Questions About eXmoor Pharma
Does eXmoor Pharma hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 MHRA GMP certificate for eXmoor Pharma.
What is eXmoor Pharma's CDMO Signal Score?
eXmoor Pharma has a Signal Score of 79/100, based on quality, operations, financial stability, and capacity data.
Evaluating eXmoor Pharma for a manufacturing program?
Use the free AI matchmaker to compare eXmoor Pharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Cell and Gene Therapy Catapult
Stevenage, UK
Signal Score: 59.0
CAR-T, Cell Therapy, AAV
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Danaher (CGT Portfolio)
Washington, DC
Signal Score: 81.5
Cell Therapy, AAV, mRNA
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein